It does this without raising IGF-1 levels, without affecting insulin sensitivity, and without promoting tissue growth beyond fat metabolism
36 The causes of the initial acute pancreatitis episodes, before starting GLP-1 receptor agonist therapy, were idiopathic in 77 patients (48%), gallstones in 49 (30%), alcohol use in 21 (13%), hypertriglyceridemia in 9 (6%), and medication related in five (3%)
The concentration is higher than intended
Below are some commonly observed symptoms
The table below shows dosing for all three formulations: Egrifta SV (the current main product), Egrifta WR (a newer once-weekly-reconstitution version), and legacy Egrifta (the original 2 mg/day product used in trials)
Its biological meaning depends heavily on context, including the tissue being studied, the local oxidative environment, the NOS isoform involved, and the timing of measurement after experimental injury or stimulation